Michael Komajda

Q: What Schools Are Affiliated With Michael Komajda

Michael Komajda is affiliated with the following schools: University of Alberta, Medical University of South Carolina, McMaster University, Monash University

Michael Komajda's AcademicInfluence.com Rankings

Michael Komajda

Medical

#1977

World Rank

#2365

Historical Rank

Cardiology

#162

World Rank

#167

Historical Rank

medical Degrees

Michael Komajda

Philosophy

#5818

World Rank

#8726

Historical Rank

Logic

#3028

World Rank

#4122

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Michael Komajda's Degrees

Doctorate Medicine Université Paris Cité
PhD Cardiology Université Paris Cité

Why Is Michael Komajda Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael Komajda's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). (2013) (6036)
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. (2005) (5789)
Effects of torcetrapib in patients at high risk for coronary events. (2007) (2393)
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study (2010) (1777)
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial (2003) (1756)
Irbesartan in patients with heart failure and preserved ejection fraction. (2008) (1749)
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. (2003) (1421)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial (2009) (1317)
Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy (2003) (1209)
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. (2005) (1207)
EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. (2006) (1170)
Rosuvastatin in older patients with systolic heart failure. (2007) (905)
Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency† (2014) (837)
The 2013 ESH/ESC guidelines for the management of arterial hypertension (2013) (805)
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. (2007) (800)
State of the art: Using natriuretic peptide levels in clinical practice (2008) (780)
The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment (2003) (738)
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. (2020) (736)
The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. (2003) (724)
Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. (2016) (691)
Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. (2005) (580)
Altered sarcoplasmic reticulum Ca2(+)-ATPase gene expression in the human ventricle during end-stage heart failure. (1990) (532)
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial (2009) (525)
Effect of nesiritide in patients with acute decompensated heart failure. (2011) (516)
Cardiac myosin binding protein–C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy (1995) (453)
Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. (1999) (440)
Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction (2011) (432)
Atlas of the clinical genetics of human dilated cardiomyopathy. (2014) (432)
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology (2018) (402)
Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. (2004) (399)
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial (2010) (381)
Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology (2007) (374)
Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). (2006) (312)
Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. (1997) (312)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD (2020) (310)
Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) Trial (2010) (309)
A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. (2011) (293)
Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. (1997) (288)
Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. (1998) (281)
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy (2011) (275)
Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. (2008) (268)
Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. (2013) (252)
Risk stratification in chronic heart failure. (1998) (247)
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. (2012) (246)
Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. (2008) (245)
Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure (2010) (239)
Prognostic value of plasma endothelin-1 in patients with chronic heart failure. (1997) (233)
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial (2010) (231)
Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction: Findings From the I-PRESERVE Trial (2011) (229)
The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. (2006) (227)
Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study (2012) (221)
Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I‐PRESERVE trial (2008) (218)
[Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: executive summary (update 2005)]. (2005) (214)
Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction: Findings From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE) (2011) (211)
Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. (2005) (198)
Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. (2011) (196)
Physicians' adherence to guideline‐recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey (2016) (193)
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. (2005) (191)
Heart failure with preserved ejection fraction: a clinical dilemma. (2014) (190)
Molecular basis of familial cardiomyopathies. (1995) (185)
Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response (2015) (178)
Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry (2017) (177)
Mapping of a novel gene for familial hypertrophic cardiomyopathy to chromosome 11 (1993) (173)
Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. (1997) (173)
Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients With Heart Failure and Preserved Ejection Fraction: The Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) Trial (2012) (172)
Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations (2003) (170)
Mutation screening in dilated cardiomyopathy: prominent role of the beta myosin heavy chain gene. (2005) (166)
Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey (2005) (163)
Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). (2009) (161)
[Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)]. (2005) (159)
Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II (2008) (158)
Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. (2015) (154)
Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). (2012) (152)
Results of a reevaluation of cardiovascular outcomes in the RECORD trial. (2013) (147)
The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. (2005) (146)
The Benefits of Early Combination Treatment of Carvedilol and an ACE-Inhibitor in Mild Heart Failure and Left Ventricular Systolic Dysfunction. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN) (2004) (146)
A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. (2008) (143)
Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study (2012) (143)
Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo‐controlled trial (2017) (143)
A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination (2005) (143)
Danon’s disease as a cause of hypertrophic cardiomyopathy: a systematic survey (2004) (142)
Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes: Lessons Learned and Directions Forward (2010) (141)
Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy (1998) (140)
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol (2005) (140)
Renal Dysfunction in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction: Impact of the New Chronic Kidney Disease-Epidemiology Collaboration Group Formula (2012) (134)
Predictors of fatal and non‐fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A‐1, high‐sensitivity C‐reactive peptide and N‐terminal pro B‐type natriuretic peptide (2009) (131)
A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. (2014) (126)
Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey (2007) (124)
Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials (2009) (123)
The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. (1997) (120)
Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy. (1996) (119)
The current and future management of acute heart failure syndromes. (2010) (118)
Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. (2013) (118)
Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction) (2017) (117)
Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. (2004) (116)
Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I. (2007) (114)
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure (2019) (114)
Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. (2000) (112)
Skeletal actin mRNA increases in the human heart during ontogenic development and is the major isoform of control and failing adult hearts. (1991) (112)
Genetic Association Study Identifies HSPB7 as a Risk Gene for Idiopathic Dilated Cardiomyopathy (2010) (110)
Factors Associated With Outcome in Heart Failure With Preserved Ejection FractionClinical Perspective (2011) (109)
Prevalence of ECG abnormalities in an international survey of patients with suspected or confirmed heart failure at death or discharge (2007) (108)
Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta‐analysis † (2012) (107)
Management of patients with heart failure in clinical practice: differences between men and women (2007) (104)
Should beta‐blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET (2007) (104)
Genotype-phenotype correlations in familial hypertrophic cardiomyopathy. A comparison between mutations in the cardiac protein-C and the beta-myosin heavy chain genes. (1998) (103)
Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study. (2000) (103)
Characterization of a Unique Genetic Variant in the β1-adrenoceptor Gene and Evaluation of its Role in Idiopathic Dilated Cardiomyopathy (1999) (102)
Review of current and investigational pharmacologic agents for acute heart failure syndromes. (2007) (102)
Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction: Results of the I-PRESERVE Collagen Substudy (2011) (100)
Mutations in the Z-band protein myopalladin gene and idiopathic dilated cardiomyopathy. (2008) (99)
Heart rate reduction in cardiovascular disease and therapy (2010) (99)
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction (2020) (98)
Prevalence of anemia in patients with chronic heart failure and their clinical characteristics. (2004) (97)
Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes (2017) (97)
Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. (2013) (96)
Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. (2013) (96)
Factors predicting mortality in idiopathic dilated cardiomyopathy. (1990) (94)
Familial hypertrophic cardiomyopathy. Microsatellite haplotyping and identification of a hot spot for mutations in the beta-myosin heavy chain gene. (1993) (94)
Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET (2002) (93)
Rationale and design of a randomized, double‐blind, placebo‐controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT) (2010) (93)
Exome-wide association study reveals novel susceptibility genes to sporadic dilated cardiomyopathy (2017) (92)
Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta‐analysis (2018) (92)
Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). (2010) (90)
Penetrance of familial hypertrophic cardiomyopathy. (1997) (90)
Rosiglitazone RECORD study: glucose control outcomes at 18 months (2007) (88)
Double heterozygosity for mutations in the β-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy (1999) (87)
Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I‐Preserve) (2014) (83)
Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction (2016) (82)
Prognostic importance of plasma NT‐pro BNP in chronic heart failure in patients treated with a β‐blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial (2007) (81)
From abstract to impact in cardiovascular research: factors predicting publication and citation (2012) (80)
Epidemiology of desmin and cardiac actin gene mutations in a european population of dilated cardiomyopathy. (2000) (80)
Physicians' guideline adherence is associated with long‐term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry (2019) (80)
Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. (2005) (78)
Genetic testing and genetic counselling in hypertrophic cardiomyopathy: the French experience (2002) (77)
Clinical evaluation of cardiovascular devices: principles, problems, and proposals for European regulatory reform. Report of a policy conference of the European Society of Cardiology. (2011) (76)
Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. (2014) (75)
International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction (2015) (75)
Recall of lifestyle advice in patients recently hospitalised with heart failure: A EuroHeart Failure Survey analysis (2007) (75)
Mutations in the ANKRD1 gene encoding CARP are responsible for human dilated cardiomyopathy. (2009) (75)
The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction). (2015) (75)
A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). (2006) (74)
International variations in the treatment and co‐morbidity of left ventricular systolic dysfunction: Data from the EuroHeart Failure Survey (2007) (73)
Correlation between left ventricular hypertrophy and GAA trinucleotide repeat length in Friedreich's ataxia. (1997) (72)
Predictors of short term mortality in heart failure - insights from the Euro Heart Failure survey. (2010) (72)
Tolerability of carvedilol and ACE‐Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE‐Inhibitor Remodelling Mild CHF EvaluatioN) (2004) (72)
Functional consequences of an LMNA mutation associated with a new cardiac and non‐cardiac phenotype (2003) (72)
Guidelines for the diagnosis and treatment of Chronic Heart Failure: full text (update 2005) The Task Force for the diagnosis and treatment of CHF of the European Society of Cardiology (2005) (70)
Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study (2013) (70)
Detection of enteroviruses in endomyocardial biopsy by molecular approach (1992) (66)
A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction (2014) (66)
Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. (2019) (65)
Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT‐HF randomized phase 2 trial (2017) (64)
Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial (2012) (62)
Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial (2015) (62)
Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. (2010) (62)
Identification of a genetic risk factor for idiopathic dilated cardiomyopathy. Involvement of a polymorphism in the endothelin receptor type A gene. CARDIGENE group. (1999) (62)
Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure (2013) (61)
Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology (2009) (60)
A 22-Year Follow-up Study of Long-term Cardiac Outcome and Predictors of Survival in Friedreich Ataxia. (2015) (60)
Homozygotes for a R869G mutation in the beta -myosin heavy chain gene have a severe form of familial hypertrophic cardiomyopathy. (2000) (60)
The safety of amiodarone in patients with heart failure. (2007) (59)
New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey. (2008) (59)
Twenty‐four‐hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy (2015) (58)
Changes in N‐terminal pro‐B‐type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I‐Preserve study (2015) (57)
Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial). (2015) (57)
Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. (2019) (57)
Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure. (2003) (57)
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction (2021) (57)
Cardiac hypertrophy and function in asymptomatic acromegaly. (1991) (56)
Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in genotyped children. (1998) (56)
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. (2007) (56)
Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT (2014) (56)
A new locus for autosomal dominant dilated cardiomyopathy identified on chromosome 6q12-q16. (2001) (55)
Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. (2009) (54)
Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. (2000) (53)
Nonpharmacologic measures and drug compliance in patients with heart failure: data from the EuroHeart Failure Survey. (2007) (51)
Familial hypertrophic cardiomyopathy. Cardiac ultrasonic abnormalities in genetically affected subjects without echocardiographic evidence of left ventricular hypertrophy. (1998) (50)
Apical left ventricular aneurysm without atrio‐ventricular block due to a lamin A/C gene mutation (2003) (50)
Intracardiac conduction defects in dystrophia myotonica. Electrophysiological study of 12 cases. (1980) (49)
Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta‐analysis (2015) (49)
Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. (2013) (48)
Sustainable Development Goals and the Future of Cardiovascular Health: A Statement From the Global Cardiovascular Disease Taskforce (2014) (46)
Risk following hospitalization in stable chronic systolic heart failure (2013) (46)
Genotype‐phenotype analysis in four families with mutations in β‐myosin heavy chain gene responsible for familial hypertrophic cardiomyopathy (1998) (46)
Rationale and design of the CONFIRM‐HF study: a double‐blind, randomized, placebo‐controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency (2014) (45)
Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). (2014) (45)
Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction (2019) (44)
Comparative value of tissue Doppler imaging and m-mode color Doppler mitral flow propagation velocity for the evaluation of left ventricular filling pressure. (2005) (44)
Characterization of a unique genetic variant in the beta1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. CARDIGENE Group. (1999) (44)
Effect of carvedilol and metoprolol on the mode of death in patients with heart failure (2007) (44)
Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk Model. (2015) (43)
Muscular blood flow response to submaximal leg exercise in normal subjects and in patients with heart failure. (1996) (42)
Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials (2016) (42)
A new polymorphism in human calmodulin III gene promoter is a potential modifier gene for familial hypertrophic cardiomyopathy. (2009) (42)
The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT (2013) (41)
Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round‐table think tank on acute heart failure, 12 May 2009 (2011) (40)
Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase. (2011) (40)
Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post‐hoc analysis of SHIFT (2016) (38)
History of Atrial Fibrillation as a Risk Factor in Patients With Heart Failure and Preserved Ejection Fraction (2014) (38)
Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT (2018) (38)
Early identification of mutation carriers in familial hypertrophic cardiomyopathy by combined echocardiography and tissue Doppler imaging. (2010) (38)
Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction (2015) (38)
Accuracy of European diagnostic criteria for familial hypertrophic cardiomyopathy in a genotyped population. (2003) (37)
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study) (2008) (37)
Cardiomyopathy in Friedreich's ataxia: a Doppler-echocardiographic study. (1992) (37)
Exchange of β‐blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial) (2004) (36)
Prevalence of memory disorders in ambulatory patients aged ≥70 years with chronic heart failure (from the EFICARE study). (2014) (36)
Relation between QT duration and maximal wall thickness in familial hypertrophic cardiomyopathy (2002) (35)
Heart rate and its reduction in chronic heart failure and beyond (2017) (35)
Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects. (2002) (35)
The Impact of Patients With Cardiac Amyloidosis in HFpEF Trials. (2021) (35)
Ambulatory heart failure management in private practice in France. (2001) (33)
Cardiologists' awareness and perceptions of guidelines for chronic heart failure. The ADDress your Heart survey (2008) (33)
Prenatal molecular diagnosis in hypertrophic cardiomyopathy: report of the first case (2004) (32)
Polymorphisms of genes of the cardiac calcineurin pathway and cardiac hypertrophy (2003) (31)
Accelerating progress on non-communicable diseases (2013) (30)
Plasma levels and molecular forms of proatrial natriuretic peptides in healthy subjects and in patients with congestive heart failure. (1996) (30)
The future of clinical trials in secondary prevention after acute coronary syndromes. (2011) (30)
Current challenges in the management of heart failure. (2015) (29)
Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure (2013) (29)
Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. (2017) (29)
Familial hypertrophic cardiomyopathy: the same mutation, different prognosis. Comparison of two families with a long follow-up. (2003) (28)
Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis. (2016) (28)
Mutational analysis of the β‐ and δ‐sarcoglycan genes in a large number of patients with familial and sporadic dilated cardiomyopathy (2003) (27)
Molecular genetics in hypertrophic cardiomyopathy: towards individualized management of the disease (2006) (27)
Angiotensin converting enzyme inhibition: from viper to patient (2000) (27)
Pregnancy in women with a cardiomyopathy: Outcomes and predictors from a retrospective cohort. (2017) (27)
Charcot–Marie–Tooth features and maculopathy in a patient with Danon disease (2004) (27)
[Cardiomyopathy in the peripartum period: current aspects. A multicenter study. 11 cases]. (1990) (27)
EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). (2016) (27)
Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial (2012) (27)
Familial dilated cardiomyopathy: clinical features in French families (1999) (26)
Severe dilated cardiomyopathy and quadriceps myopathy due to lamin A/C gene mutation: A phenotypic study (2006) (26)
Abdominal obesity is associated with ineffective control of cardiovascular risk factors in primary care in France. (2008) (25)
Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial). (2016) (25)
Renal Dysfunction in Heart Failure Patients with Preserved versus Reduced Ejection Fraction: Impact of the New CKD-EPI Formula (2012) (25)
Mutational analysis of the beta- and delta-sarcoglycan genes in a large number of patients with familial and sporadic dilated cardiomyopathy. (2003) (25)
Consensus of the French Society of Gerontology and Geriatrics and the French Society of Cardiology for the management of coronary artery disease in older adults. (2009) (25)
First description of germline mosaicism in familial hypertrophic cardiomyopathy (2000) (25)
Unresolved issues in the management of chronic stable angina. (2015) (25)
Effects of arginine vasopressin and extracellular osmolarity on atrial natriuretic peptide release by superfused rat atria. (1991) (25)
Genetic aspects of heart failure (1999) (24)
Variations in plasma endothelin concentrations during coronary spasm. (1993) (24)
Commentary: International collaboration needed on device clinical standards (2011) (24)
Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure (2013) (24)
Desmosomal Cadherins Are Decreased in Explanted Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patient Hearts (2013) (24)
Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population (2015) (23)
[European study of ambulatory management of heart failure by cardiologists]. (2004) (23)
Sustainable development goals and the future of cardiovascular health: a statement from the Global Cardiovascular Disease Taskforce. (2014) (23)
Involvement of BAG3 and HSPB7 loci in various etiologies of systolic heart failure: Results of a European collaboration assembling more than 2000 patients. (2013) (22)
Exclusion of HRAS from long QT locus (1994) (22)
Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. (2013) (22)
A novel genetic variant in the transcription factor Islet‐1 exerts gain of function on myocyte enhancer factor 2C promoter activity (2013) (22)
Non‐adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT (2016) (22)
Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. (2015) (21)
Dilated cardiomyopathy and the level of alcohol consumption: a planned multicentre case-control study. (1986) (21)
Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes (2011) (21)
Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris (2015) (20)
Cardiovascular Diseases in Europe Euro Heart Survey and National Registries of Cardiovascular Diseases and Patient Management (2006) (20)
Effect of Visit‐to‐Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the I f Inhibitor Ivabradine Trial (SHIFT) Trial (2016) (20)
Identification of a mutation near a functional site of the beta cardiac myosin heavy chain gene in a family with hypertrophic cardiomyopathy. (1994) (20)
Brain natriuretic peptide usefulness in very elderly dyspnoeic patients: the BED study (2017) (20)
Repeated heart rate measurement and cardiovascular outcomes in left ventricular systolic dysfunction. (2015) (20)
Heart failure with preserved systolic function: a diagnostic algorithm for a pragmatic definition. (2006) (19)
Sustainable Development goals and the future of cardiovascular health: a statement from the Global Cardiovascular Disease Taskforce. (2014) (19)
Are we ready for pharmacogenomics in heart failure? (2001) (19)
Design of the Heart failure Endpoint evaluation of AII‐Antagonist Losartan (HEAAL) study in patients intolerant to ACE‐inhibitor (2008) (19)
Left atrial volume predicts abnormal exercise left ventricular filling pressure (2014) (19)
Thromboembolism in heart failure, old ideas and new challenges (2001) (19)
Effects of prolonged propranolol treatment on left ventricular remodeling and oxidative stress after myocardial infarction in rats. (2000) (19)
Low level exercise echocardiography helps diagnose early stage heart failure with preserved ejection fraction: a study of echocardiography versus catheterization (2017) (18)
Plasma calcitonin gene-related peptide decreases in chronic congestive heart failure. (1992) (18)
Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial. (2015) (18)
Effects of indapamide on left ventricular mass and function in systemic hypertension with left ventricular hypertrophy. (1990) (18)
Screening of genes encoding junctional candidates in arrhythmogenic right ventricular cardiomyopathy/dysplasia. (2013) (18)
Myocarditis during acute schistosomiasis in two travelers. (2010) (18)
Long-term outcome after bare-metal or drug-eluting stenting for allograft coronary artery disease. (2010) (17)
Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I‐PRESERVE) trial (2016) (17)
Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure (2021) (17)
Plakophilin 2A is the dominant isoform in human heart tissue: consequences for the genetic screening of arrhythmogenic right ventricular cardiomyopathy (2011) (17)
Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. (2019) (17)
Below-knee arterial calcification in type 2 diabetes: association with receptor activator of nuclear factor κB ligand, osteoprotegerin, and neuropathy. (2014) (17)
PARADIGM-HF--the experts' discussion. (2014) (17)
Genes and their polymorphisms in mono- and multifactorial cardiomyopathies: towards pharmacogenomics in heart failure. (2002) (17)
Mode of presentation and mortality amongst patients hospitalized with heart failure? A report from the First Euro Heart Failure Survey (2018) (16)
Patient journey in decompensated heart failure: An analysis in departments of cardiology and geriatrics in the Greater Paris University Hospitals. (2017) (16)
[HLA A-B and DR in dilated myocardiopathies]. (1987) (16)
Comparison of Outcome Adjudication by Investigators and by a Central End Point Committee in Heart Failure Trials (2020) (16)
Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry (2021) (15)
[Expert consensus of the French society of geriatrics and gerontology and the French society of cardiology on the management of atrial fibrillation in elderly people]. (2013) (15)
Quality of Physician Adherence to Guideline Recommendations for Life-saving Treatment in Heart Failure: an International Survey. (2017) (15)
[Familial hypertrophic cardiomyopathy. French study of the duration and outcome of pregnancy]. (2002) (15)
Left coronary artery aneurysm and anteroseptal acute myocardial infarction following blunt chest trauma. (1986) (14)
Anemia in chronic heart failure: should we treat it and how? (2007) (14)
Pilot Study of Cardiovascular Effects of Nebivolol in Congestive Heart Failure (1991) (14)
Diagnostic accuracy of a 2D left ventricle hypertrophy score for familial hypertrophic cardiomyopathy. (2005) (14)
Detection of myocarditis during the first year after discovery of a dilated cardiomyopathy by endomyocardial biopsy and gallium-67 myocardial scintigraphy: prospective multicentre French study of 91 patients. (1988) (14)
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. (2021) (14)
Glomerular atrial natriuretic factor receptors in experimental congestive heart failure. (1993) (13)
A familial form of conduction defect related to a mutation in the PRKAG2 gene. (2007) (13)
Global and regional echocardiographic strain to assess the early phase of hypertrophic cardiomyopathy due to sarcomeric mutations. (2019) (13)
Familial and sporadic hypertrophic myopathy: differences and similarities in a genotyped population. A long follow-up study. (2008) (13)
Improving outcomes in chronic heart failure. (2006) (12)
Detection of enteroviruses in endomyocardial biopsy by molecular approach. (1993) (12)
Parasympathetic activity in Friedreich's ataxia☆ (1996) (12)
A Description of the Clinical Characteristics at Baseline of Patients Recruited into the Carvedilol or Metoprolol European Trial (COMET) (2004) (11)
Doppler Echocardiography in Familial Hypertrophic Cardiomyopathy (1995) (11)
The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up (2018) (11)
[Recommendations for the diagnosis and management of cardic failure in the elderly subject]. (2004) (10)
Years‐needed‐to‐treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials (2009) (10)
The role of the neurohormonal system in heart failure (1998) (10)
Clinical Outcomes at 180 days in the ASCEND-HF Trial: Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (2011) (10)
Management of heart failure in the elderly: recommendations from the French Society of Cardiology (SFC) and the French Society of Gerontology and Geriatrics (SFGG). (2006) (9)
Idiopathic dilated cardiomyopathy: lack of association with haemochromatosis gene in the CARDIGENE study (2001) (9)
Eff ects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure ( HEAAL study ) : a randomised , double-blind trial (2009) (9)
The wealth of nations and the dissemination of cardiovascular research. (2013) (8)
Right heart failure due to an inter-atrial shunt after percutaneous mitral balloon dilatation. (1989) (8)
Role of ivabradine in management of stable angina in patients with different clinical profiles (2018) (8)
Captopril does not acutely modulate plasma endothelin-1 concentration in human congestive heart failure (1996) (8)
Genetics of familial hypertrophic cardiomyopathy Results and strategies. (1993) (8)
Treatment of heart failure with preserved systolic function. (2008) (8)
835-2 Carvedilol better protects against vascular events than metoprolol in heart failure: Results from COMET (2004) (8)
[Epidemiology of cardiovascular complications of diabetes]. (1999) (8)
[Adherence to guidelines in CHF therapy in Germany]. (2005) (7)
Feasibility of outpatient coronary angiography with "ad hoc" angioplasty. (2008) (7)
[Genetics of cardiovascular diseases]. (1997) (7)
Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction (2020) (7)
Replacement of angiotensin converting enzyme inhibition by carvedilol results in long-term reversed left ventricular remodeling in mild heart failure and is well tolerated: Results of the CARMEN (Carvedilol aceinhibitor remodeling in mild heart failure evaluation) study (2003) (7)
Covariate adjusted reanalysis of the I-Preserve trial (2020) (7)
The beat goes on: on the importance of heart rate in chronic heart failure. (2012) (7)
MORBIDITY AND MORTALITY IN DIABETICS WITH HEART FAILURE AND A PRESERVED EJECTION FRACTION: RESULTS FROM THE I-PRESERVE TRIAL (2013) (7)
[Diagnosis and treatment of chronic heart disease. Guidelines of the European Society of Cardiology. Revision 2005]. (2005) (7)
L'étude ATLAS (assessment of treatment with lisinopril and survival) ; justification et objectifs (1994) (7)
ESSENTIAL – The Studies of Oral Enoximone Therapy in Advanced Heart Failure (2005) (7)
Relation between severity of left ventricular systolic dysfunction and repolarisation abnormalities on the surface ECG: a report from the Euro heart failure survey (2006) (7)
Implantable left ventricular assist systems (LVAS): Recent results. A report from a series of meetings sponsored by the Study Group on Advanced Heart Failure of the Working Group on Heart Failure (2000) (7)
Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. (2019) (7)
DEFINITIONS ET CLASSIFICATION DES CARDIOMYOPATHIES (1996) (7)
Are angiotensin II receptor blockers indicated in chronic heart failure? (2002) (6)
Genetics of dilated cardiomyopathy: a molecular maze? (2000) (6)
Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy (2019) (6)
Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. (2020) (6)
[Management of heart failure: a challenge for healthcare systems]. (2012) (6)
The Year in Cardiology 2015: Heart Failure (2016) (6)
[The ATLAS study (Assessment of Treatment with Lisinopril and Survival); justification and objectives]. (1994) (6)
Relationships between the antihypertensive effects of bisoprolol and levels of plasma atrial natriuretic peptide in hypertensive patients (2002) (6)
Heart rate in chronic heart failure: an overlooked risk factor. (2015) (6)
Parasympathetic activity in Friedrich's ataxia. (1996) (5)
Hemodynamic and neurohormonal effects of flosequinan in patients with heart failure (1997) (5)
Genome wide association analysis in dilated cardiomyopathy reveals two new key players in systolic heart failure on chromosome 3p25.1 and 22q11.23 (2020) (5)
[Non invasive evaluation of cardiovascular effects of nebivolol in patients with cardiac insufficiency]. (1992) (5)
Exclusion of genes coding for proteins of the cytoskeleton and the extracellular matrix in familial hypertrophic cardiomyopathy using a candidate gene approach. (1993) (5)
Sunday, 26 August 2012 (2012) (5)
Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and AnginaCLINICAL PERSPECTIVE (2015) (5)
184 Effect of long-term treatment with carvedilol compared to metoprolol on heart failure morbidity and diabetes in COMET (2004) (5)
[Idiopathic cardiomyopathies]. (2002) (5)
Clinical profile and outcome of anaemic patients with chronic heart failure in the COMET trial (2004) (4)
Abstract 3814: Cardiac Structural Changes and Diastolic Function in Heart Failure with Preserved Ejection Fraction - Importance of Left Atrial Volume: the iPRESERVE Study (2006) (4)
The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart FailureWith Preserved Ejection Fraction (4)
835-3 Beta-blocker dose does not influence the beneficial effects of carvedilol compared to metroprolol in the patients with heart failure: Results from the carvedilol or Metoprolol European Trial (COMET) (2004) (4)
Liraglutide in heart failure: caution is needed (2017) (4)
Guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes (EASD) (2020) (4)
Do patients necessarily have to start with an angiotension converting enzyme inhibitor in the treatment of heart failure? Results of the CARMEN (Carvedilol ACE Inhibitor Remodeling Mild CHF Evaluation) study (2003) (4)
Long-term treatment of congestive heart failure with captopril. (1982) (4)
How will the human genome project change cardiovascular medicine? (2001) (4)
The Euroheart failure survey: symptoms and quality of life (2002) (4)
[Heart involvement in diabetic patients]. (1990) (4)
[Evaluation of a specific French scale of activity in chronic heart failure. A national multicenter study. Group for Cardiac Insufficiency and Cardiomyopathy of the French Society of Cardiology]. (1999) (4)
Asymptomatic left ventricular dysfunction in patients with type 2 diabetes free of cardiovascular disease and its relationship with clinical characteristics: The DIACAR cohort study (2020) (4)
Genetic factors in familial hypertrophic cardiomyopathy: does molecular cardiology offer new perspectives? (1996) (4)
[Early postoperative thrombosis of an aortic Saint-Jude prosthesis. Success of fibrinolytic treatment]. (1988) (3)
Championing cardiovascular health innovation in Europe (2013) (3)
Annual scientific report 2000–2001 Working group on Heart failure (#19) European Society of Cardiology (2001) (3)
How well are we implementing evidence‐based care? (2009) (3)
Treatment of advanced chronic heart failure with normal left ventricular ejection fraction. Response to the letter by Dr. Martinez‐Selles (2007) (3)
[Myocardial involvement in 2 women, carriers of Duchenne de Boulogne muscular dystrophy]. (1991) (3)
[Holter monitoring in patients with focal cerebral ischaemic attacks (author's transl)]. (1981) (3)
835-4 Comparison of the effects of metoprolol and carvedilol on symptoms, well-being, and quality-adjusted life-years: A description of the patient-journey in COMET (2004) (3)
Financial impact of ivabradine on reducing heart failure penalties under the Hospital Readmission Reduction Program (2017) (3)
Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. (2021) (3)
A new approach for the identification of modifier genes in heart failure (2004) (3)
Monday, 27 August 2012 (2012) (3)
Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. (2015) (3)
Heart rate decrease: a new paradigm in the treatment of heart failure. Insights from the SHIFT study. (2011) (2)
ACUTE CORONARY SYNDROMES IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION: A HARBINGER OF DEATH? (2010) (2)
The heart of genomics (2001) (2)
223 Relationship between QRS duration and medical therapy in heart failure - a report from Euro Heart Failure survey (2005) (2)
MARKERS OF EXTRACELLULAR MATRIX TURNOVER AND RISK OF DEATH IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION: RESULTS FROM I-PRESERVE (2015) (2)
[Treatment of torsade des pointes by intravenous magnesium]. (1986) (2)
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial. (2022) (2)
[Analysis of predictive factors of mortality in dilated cardiomyopathy. A cooperative study by the Cardiomyopathy Working Group]. (1990) (2)
Prognostic and symptomatic benefits with ivabradine: lessons from the SHIFT trial (2015) (2)
1012-121 Lack of heart rate effects on the mortality benefits of carvedilol compared to metoprolol in the patients with heart failure: Results from the carvedilol or metoprolol European trial (COMET) (2004) (2)
[Heart failure in men and women: important differences in the diagnostic workup and treatment]. (2008) (2)
How can the European Society of Cardiology ensure compliance with ethical standards? (2016) (2)
The COX8 gene is not the disease gene of the CMH4 locus in familial hypertrophic cardiomyopathy. (1995) (2)
412 Influence of QRS width on the clinical features of heart failure: data from the euroheart failure study (2003) (2)
BETA BLOCKER DOSAGE AND USE OVER TIME IN THE SYSTOLIC HEART FAILURE TREATMENT WITH THE IF INHIBITOR IVABRADINE TRIAL (SHIFT) STUDY (2015) (2)
HEART FAILURE WITH PRESERVED EJECTION FRACTION: MORTALITY RISK POST FIRST HOSPITALIZATION - DATA FROM I-PRESERVE (2010) (2)
The Baseline Characteristics of Patients Enrolled in the Irbesartan in Heart Failure with Preserved Systolic Function Trial Are Similar to Those in the Community but Differ from CHARM-Preserved (2006) (2)
Abstract 14299: The Prognostic Value of Insulin-like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Ejection Fraction: Results From Irbesartan in Heart Failure and Preserved Ejection Fraction (I-PRESERVE) Trial (2015) (2)
1001-26 Exchange of beta-blocking therapy in heart failure patients. Experiences from the post study phase of COMET (the carvedilol or metoprolol European trial) (2004) (2)
Myocardial levels of atrial natriuretic factor and of its mRNA are highly variable in end-stage heart failure (1990) (2)
[Observations on the management of cardiac failure in ambulatory patients. Results of a survey of cardiologists]. (2001) (2)
Are angiotensin II receptor antagonists indicated in chronic heart failure? (2002) (2)
Aging increases circulating BH2 without modifying BH4 levels and impairs peripheral vascular function in healthy adults. (2021) (2)
Model-based determination of cut-off values for left ventricular hypertrophy from echocardiographic myocardial mass data. (1992) (2)
Cardiomyopathies primitives : Insuffisances cardiaques (2002) (2)
246Effect of Ivabradine on Mortality in Patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT (2017) (2)
Quantitative analysis of sarcoplasmic reticulum Ca++ATPase mRNA at the time of cardiac transplantation (1989) (2)
078 High prevalence of cognitive disorders in Heart Failure patients: results of the EFICARE survey (2011) (2)
Championing cardiovascular health innovation in Europe. (2013) (2)
064 - Temporal trends in prescription rates of recommended treatments in chronic heart failure outpatients: a comparison of three French surveys IMPACT RECO I, II & III (2010) (2)
Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States. (2016) (2)
[Review: genetics of familial dilated cardiomyopathy]. (2005) (2)
Ivabradine and outcomes in chronic heart failure – Authors' reply (2010) (1)
Systematic echo-doppler screening identifies subtle structural and functional cardiac abnormalities in type 2 diabetes mellitus without documented cardio vascular disease: DIACAR a prospective study (2020) (1)
Efficacy and Safety of Ivabradine in Patients with Chronic Systolic Heart Failure and Low Blood Pressure in the SHIFT Trial (2013) (1)
Pharmacological management of chronic heart failure (2017) (1)
Highlights of the 2006 scientific sessions of the European Society of Cardiology: Barcelona, Spain, September 2-5, 2006. (2006) (1)
Abstract 3146: The Relation of Quality of Life Score to Outcome in Heart Failure With Preserved Ejection Fraction: Findings From the Irbesartan in Heart Failure With Preserved Ejection Fraction Trial (I-PRESERVE) (2009) (1)
Standards need international collaboration (2011) (1)
835-1 A comparison of adverse events occurring with carvedilol or metoprolol in the treatment of heart failure: Results from COMET (2004) (1)
Heart Failure Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction (2010) (1)
The development of an international, common, prospective, cardiology database. Report of the joint G8 Cardio-Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO)—Societé Française de Cardiologie (SFC) database committee (2009) (1)
Effects of Heart Rate Reduction in Black Patients from the SHIFT (Systolic Heart Failure treatment with the If Inhibitor Ivabradine Trial) Study (2015) (1)
653 Atrial fibrillation is associated with increased risk of fatal and non‐fatal cardiovascular events in patients with heart failure and preserved ejection fraction: findings from the I‐PRESERVE trial (2008) (1)
Correction: Exome-wide association study reveals novel susceptibility genes to sporadic dilated cardiomyopathy (2020) (1)
286 Familial and sporadic hypertrophic cardiomyopathy: differences and similarities in a genotyped population. A follow-up study (2006) (1)
Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis (2013) (1)
Mortality risk stratification in Chronic Heart Failure patients: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) (2012) (1)
[Prognostic value of neurohormones in heart failure in clinical practice]. (2002) (1)
0481: Clinical profile of patients hospitalized for acute heart failure in cardiology and in geriatrics. A survey in greater Paris University hospitals (2016) (1)
Championing cardiovascular health innovation in Europe. (2013) (1)
The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure (2013) (1)
Effect of pravastatin during regressive phase of diet-induced pigeon atherosclerosis (1994) (1)
Pretest probability of a normal echocardiography: validation of a simple and practical algorithm for routine use. (2014) (1)
Abstract 342: Prognostic Implications of Low Cholesterol and Statin Therapy in Heart Failure - the “Cholesterol Paradox” (2006) (1)
Effect of Comorbidities and Risk Factors on Outcomes and Ivabradine’s Effects in Patients With Chronic Systolic Heart Failure in the SHIFT Trial (2015) (1)
Bene fi cial effects of ivabradine in patients with heart failure , low ejection fraction , and heart rate above 77 (2019) (1)
Abstract 18395: Safety of Continuing Ivabradine Treatment During Hospitalization for Worsening of Heart Failure in the SHIFT Study (2015) (1)
What is the role of heart rate in cardiac remodeling (2015) (1)
Lessons from the European heart survey. (2006) (1)
Cardiac Safety of the Sino Atrial Node f Channel Blocker Ivabradine in Chronic Heart Failure: An ECG-Holter Sub-study (2014) (1)
Carvedilol treatment is as well tolerated as angiotensin converting enzyme inhibition in patients with chronic heart failure: Results of the CARMEN (Carvedilol ACE inhibitor remodeling mild CHF evaluation) study (2003) (1)
[Efficacy and side effects of long-term treatment with amiodarone. Retrospective study. Apropos of 460 cases]. (1985) (1)
183 Carvedilol has a better protective effect against major vascular events than metoprolol in heart failure ‐ Results from the COMET study (2004) (1)
[New cardiotonic agents]. (1986) (1)
Heart failure guidelines in North America and Europe: agreement or disagreement? (2009) (1)
36 Diabetes is associated with increased risk of CV events in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Systolic Function Trial (2008) (1)
Should beta-blocker therapy be reduced or withdrawn in patients with worsening heart failure? insights from COMET (2004) (1)
[Effect of cardioversion of atrial fibrillation on left ventricular function in dilated cardiomyopathy. A multicenter study]. (1990) (1)
[Hypertrophic cardiomyopathies]. (2003) (1)
548 Treatment monitoring with brain natriuretic peptide and N‐terminal pro brain natriuretic peptide in patients with left ventricular systolic heart failure ‐ a substudy of the CARMEN trial (2003) (1)
[Mortality in cardiac insufficiency. Evaluation of prognosis, influence of treatments]. (1990) (1)
[Hemodynamic study of (nicergoline) about left ventricular heart failure (author's transl)]. (1981) (1)
Novel approaches to heart rate modulation in chronic heart failure. (2013) (1)
Long-term experience with tertatolol in hypertension. (1986) (1)
Case studies: reducing risk in patients with diabetes. (2006) (1)
SOTAGLIFLOZIN REDUCES TOTAL HOSPITALIZATIONS AND INCREASES DAYS ALIVE AND OUT OF HOSPITAL IN THE SOLOIST-WHF TRIAL (2021) (1)
Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency: Rationale and design of CONFIRM-HF study (2014) (1)
Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: efficacy and safety of Ivabradine. a SHIFT study analysis (2013) (1)
[Immunological study of primary non-obstructive myocardiopathies. A report on 37 cases (author's transl)]. (1979) (1)
Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. (2005) (1)
Personalized care of patients with heart failure: are we ready for a REWOLUTION? Insights from two international surveys on healthcare professionals' needs and patients' perceptions (2023) (1)
[Long-term treatment of chronic heart failure by an inhibitor of angiotensin converting enzyme]. (1983) (0)
0275: Borderline hypertrophic cardiomyopathy or athlete’s heart: what is the role for genetic testing in athletes? (2016) (0)
Abstract 11480: Comparison of Outcome Adjudication by Investigators and by a Central Endpoint Committee (CEC) in Heart Failure Trials: Experience of the Shift Heart Failure Study (2019) (0)
[French familial multicenter survey of hypertrophic cardiomyopathy. Initial Doppler echocardiographic results]. (1993) (0)
[Silent Q fever endocarditis. Report of a case]. (1999) (0)
072: Psychological impact of predictive genetic testing in cardiomyopathies (2013) (0)
079 - Early Identification of mutation carriers by echodoppler and TDI in familial Hypertrophic Cardiomyopathy (2010) (0)
[Primary myocardiopathies and immunology. The facts and their significance]. (1978) (0)
Gray zone fractional flow reserve 0.81–0.85 is associated with an increased risk of cardio-vascular events (2019) (0)
[First-line treatment of cardiac insufficiency: digitalis glycosides, diuretics, vasodilator agents or new cardiotonic agents?]. (1988) (0)
[Clinical application of the genetic aspects of familial hypertrophic cardiomyopathy]. (1998) (0)
Management of acute heart failure (2017) (0)
905 How may patients with heart failure are candidates for cardiac resynchronisation and/or implantable defibrillators? Data from the Euro Heart Failure Stud (2003) (0)
Artificial intelligence applied to risk stratification in heart failure: A monocentric pilot study (2020) (0)
091 Genetic analysis in independent patients with left ventricular non compaction: yield of mutation screening and identification of RBM20 as a new gene involved in the disease (2012) (0)
[Angiographic morphological study of the left ventricle in obstructive cardiomyopathy. Comparison with haemodynamic data (author's transl)]. (1981) (0)
Response to Letters Regarding Article, “Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction” (2012) (0)
0198: Global and regional echocardiographic strain to assess early phase of hypertrophic cardiomyopathy due to sarcomeric mutations (2016) (0)
[Hypertrophic and obstructive myocardiopathies]. (1981) (0)
[Heart failure: public health's problem]. (2005) (0)
Abstract of papers to be presented at the 39th Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, March 18–22, 1990Spontaneous and evoked release of atrial natriuretic peptide from the rat atriain vitro (1990) (0)
082 Chronic obstructive pulmonary disease: the new deal for b-blocker prescription in chronic heart failure (2010) (0)
610 Mechanisms involved in ischaemia, metabolism and stress adaptation / Pharmacotherapy of heart failure (2015) (0)
[Current treatments of congestive heart failure]. (1996) (0)
Abstract 15527: Association Between Adrenergic Receptor Modulation and the Risk of Heart Failure: A Two-sample Mendelian Randomization Study (2020) (0)
Abstract 11043: A Prediction Model for Sudden Cardiac Death in Patients With Heart Failure and Preserved Ejection Fraction (2014) (0)
[Definitions and classification of cardiomyopathies]. (1996) (0)
[Hemodynamic effects of ARL 115 in left ventricular insufficiency]. (1984) (0)
Poster Session 3 (2012) (0)
The MAHLER study: Validation of guidelines for the treatment of congestive heart failure (CHF) in Europe (2003) (0)
2 Borderline hypertrophic cardiomyopathy or athlete's heart: what is the role for imaging and genetic testing in athletes? (2015) (0)
Neurohormonal characteristics of patients with cardiac failure (1998) (0)
521 Factors related to the ARB prescription in patients with heart failure. Results of the IMPACT‐RECO II survey (2007) (0)
[Value and limitations of new cardiotonic agents]. (1989) (0)
Abstract 3175: A Simple Risk Score derived from Euro Heart Failure Survey to Predict Mortality in Acute Heart Failure (2006) (0)
081 Analysis of TAZ (tafazzin) and LDB3 (LIM domain-binding3/Cypher/ZASP) genes in Left ventricular non compaction (2010) (0)
[A familial form of conduction defects associated with a PRKAG2 gene mutation]. (2007) (0)
318 Specialist awareness of and adherence to clinical guidelines for management of chronic heart failure (CHF) (2007) (0)
[Apical left ventricular aneurysm without atrio-ventricular block due to a lamin A/C gene mutation]. (2005) (0)
[Conduction disturbencies in Steinert's disease. Electrophysiologic study of 12 cases]. (1979) (0)
Comments on meta-analysis of ivabradine as adjuvant treatment for chronic heart failure by Mizzaci et al. (2017) (0)
Health related quality of life in I-PRESERVE trial (2008) (0)
[Coronary stenosis after radiotherapy. Clinical study of 5 cases and review of the literature]. (1986) (0)
LONG-TERM TREATMENT OFCONGESTIVEHEART FAILURE WITHCAPTOPRIL (1982) (0)
0210: Long term follow up of cardiomyopathy in Friedreich Ataxia (2015) (0)
0316: Mid-regional pro-atrial natriuretic peptide for predicting mortality and morbidity in hypertrophic cardiomyopathy: a comparison with N-terminal pro-brain natriuretic peptide (2016) (0)
[How will drugs be prescribed in the future for patients with cardiac insufficiency?]. (2000) (0)
Impact on mortality of plasma NT-proBNP in chronic heart failure in patients treated with beta-blockers. results from COMET (2004) (0)
Geographic Variation in Clinical Course Among Patients Hospitalized for Acute Heart Failure (2011) (0)
Subject Index, Vol. 6 (Suppl. 2), 1986 (1986) (0)
Cohort profile The ESC-EORP Chronic Ischemic Cardiovascular Disease Long-Term (CICD LT) registry. (2019) (0)
108 Importance of haemodilution in haemoglobin concentrations in outpatients with chronic heart failure. Results of IMPACT-RECO Program III (2010) (0)
179 Comparison of the effects of metoprolol and Carvedilol on symptoms, well‐being and quality‐adjusted life‐years: a description of the “patient‐journey” in COMET (2004) (0)
[Immunologic study of dilated cardiomyopathies]. (1982) (0)
Sustainable Development Goals and the future of cardiovascular health. A statement from the Global Cardiovascular Disease Taskforce. (2014) (0)
0488: Predictive genetic testing in hereditary heart diseases: a single-center series of 304 subjects (2015) (0)
[Comparison of hemodynamic and histological data in hypertrophic subvalvular aortic stenosis. Therapeutic discussion (author's transl)]. (1980) (0)
Poster session 3 (2001) (0)
456 An ACEI and ARB combination in CHF outpatients: from outcome trials to clinical practice. Results from IMPACT‐RECO II survey (2007) (0)
Ivabradine Added to Standard Therapy Improves Outcomes in Patients with Systolic HF (2010) (0)
ESC National Societies Cardiovascular Journals Editors´ Network Championing cardiovascular health innovation in Europe (2013) (0)
HEART FAILURE WITH PRESERVED EJECTION FRACTION The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart FailureWith Preserved Ejection Fraction Results From the I-PRESERVE Trial ( Irbesartan in Heart Failure and Preserved Ejection Fraction ) (2017) (0)
Physicians’ Adherence to Guideline Recommended Drug Therapy in Systolic Heart Failure: Australian Data From the International Qualify Survey (2016) (0)
Abstract 3148: Atrial Fibrillation Is Associated With Increased Risk Of Fatal And Non-fatal Cardiovascular Events In Patients With Heart Failure And Preserved Ejection Fraction - Findings From The Irbesartan In Heart Failure With Preserved Systolic Function Trial (I-PRESERVE) (2007) (0)
The Challenge of Optimal Heart Failure Management: Present and Future (2011) (0)
0203: Pregnancy in women with a cardiomyopathy: outcomes and predictors from a retrospective cohort (2016) (0)
Championing cardiovascular health innovation in Europe ESC national societies cardiovascular journals editors' network (2013) (0)
532 The drug dosages are not influenced by the number of recommended treatments prescribed in chronic heart failure: results of the French survey IMPACT‐RECO (2006) (0)
[Cardiac diseases and anti-heart cellular autoimmunity]. (1978) (0)
[Noninvasive evaluation of partial beta adrenergic agonist properties of xamoterol in cardiac insufficiency]. (1990) (0)
643 Clinical and therapeutic factors affecting short term prognosis in heart failure. Insights from the Euro Heart Failure survey (2005) (0)
[Current concepts on dilated cardiomyopathies]. (1986) (0)
1012-103 Blood pressure changes do not influence the beneficial effects of carvedilol compared to metoprolol in the patients with heart failure: Results from COMET (carvedilol or metoprolol European trial) (2004) (0)
Evaluation of cardio-vascular effects of nebivolol in heart failure (1990) (0)
[Impact of Home Return Assistance Service in Heart Failure (PRADO-IC) on the one year re-hospitalisation and mortality in a heart failure hospitalized population of patients]. (2022) (0)
[Epidemiology of cardiac failure and current prognosis of the most seriously ill patients]. (1996) (0)
100 Renal dysfunction and use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic heart failure (2010) (0)
Phenotype-genotype relationships in familial hypertrophic cardiomyopathy (1999) (0)
Godina 2015 . u kardiologiji : srčano zatajivanje The year in cardiology 2015 : heart failure (2016) (0)
Heart failure with preserved ejection fraction: how do we treat it and what are the perspectives? (2013) (0)
Patients With Heart Failure and a Preserved Ejection Fraction Prevalence and Significance of Alterations in Cardiac Structure and Function in (2011) (0)
[Treatment of chronic heart failure: current views]. (1995) (0)
The top ten factors related to morbidity and mortality in patients with chronic heart failure and LVSD: a SHIFT prognostic model (2013) (0)
[The indications for pacemakers in high risk bundle branch block. A retrospective study of 40 cases with an average follow-up of 3 years (author's transl)]. (1980) (0)
252 Plakophilin2b is not expressed in the heart: consequences for the genetic screening of arrhythmogenic right ventricular cardiomyopathy (2011) (0)
Wednesday, 29 August 2012 (2012) (0)
Linkage analysis of adrenoceptor genes to familial hypertrophic cardiomyopathy (1992) (0)
[Primary pulmonary arterial hypertension. Trial treatment with nifedipine, diazoxide and isoproterenol]. (1980) (0)
[Contribution of molecular biology to the study of the initial phase of cardiac hypertrophy caused by mechanical overload]. (1979) (0)
0440: Patient journey during hospitalization for acute heart failure in cardiology and geriatric departments of greater Paris university hospitals (2016) (0)
[Mitral systolic anterior motion and left ventricular function in obstructive cardiomyopathy]. (1983) (0)
Study of the functional consequences of BAG3 molecular variants associated with human dilated cardiomyopathy (2013) (0)
Epidemiology of cardiac actin and desmin gene mutations in a European population of dilated cardiomyopathy (2000) (0)
[Contribution of genetics to cardiomyopathy]. (2002) (0)
17-23 Komajda (1999) (0)
New Data from the RECORD Study (2009) (0)
INSUFFISANCE CARDIAQUE ET CARDIOMYOPATHIES DILATEES (1998) (0)
443 Reaching target doses in ESC recommended treatments for chronic heart failure: still some place for improvement. Results of the IMPACT‐RECO II survey (2007) (0)
Join us (2002) (0)
Abstract 3640: Diabetes Mellitus is Associated with Increased Risk of Fatal and Non-Fatal Cardiovascular Events in Heart Failure Patients with Preserved Ejection Fraction - Findings From the Irbesartan in Heart Failure with Preserved Systolic Function Trial (2007) (0)
188 Incidence and type of adverse events occurring with carvedilol or metoprolol in the treatment of heart failure; results from COMET (2004) (0)
Familial dilated cardiomyopathy: Criteria for diagnosis and for family studies (1999) (0)
[Syncope of cardiac origin]. (1981) (0)
Prognostic significance and the evolution of renal insufficiency in COMET trial (2004) (0)
Author response for "Asymptomatic left ventricular dysfunction in type 2 diabetic patients free of cardio vascular disease and relationship with clinical characteristics: The DIACAR cohort study" (2020) (0)
[Long-term effects of indapamide in left ventricular hypertrophy in patients with hypertension]. (1990) (0)
[What is the role of angiotensin receptor antagonists in the treatment of cardiac failure?]. (2001) (0)
[Treating heart failure with carvedilol in private practice (initiating treatment and follow-up at one year. The KEOPS study]. (2007) (0)
[Cardiac insufficiency: what treatment? what dose? For which patients? Converting enzyme inhibitors and diuretics]. (2000) (0)
[New cardiotonic agents]. (1985) (0)
[Nitrate derivatives and cardiac insufficiency]. (1992) (0)
PCV24 THE MAHLER STUDY: DIFFERENCES IN RESOURCE USE FOR THE MANAGEMENT OF CHRONIC HEART FAILURE ACROSS 6 EUROPEAN COUNTRIES (2003) (0)
Abstract 10912: Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients with Heart Failure and Preserved Ejection Fraction: The I-PRESERVE Trial (2011) (0)
[Diagnostic value of a two-dimensional echocardiographic score for left ventricular hypertrophy validated by the Imatron CT scan in familial hypertrophic cardiomyopathy]. (2006) (0)
[Paralysing hypokalemic thyrotoxicosis]. (2000) (0)
[Supraventricular tachycardia in obstructive myocardiopathy. A retrospective study of 51 cases by the Working Group on myocardiography]. (1981) (0)
[Left ventricular insufficiency. Etiology, physiopathology, diagnosis, development, treatment]. (1992) (0)
[Beta-blockers in the treatment of heart failure]. (1990) (0)
Exclusion of desmin gene involvement in hypertrophic cardiomyopathy in several French families (1992) (0)
Abstract 3388: Baseline Plasma NT-proBNP Concentrations in Relation to Clinical Characteristics: Results from the Irbesartan in Heart Failure with Preserved Systolic Function Trial (2006) (0)
Repeated Heart Rate Measurement and Cardiovascular Outcomes in LVSD (2015) (0)
465 Prevalence and management of heart failure in very elderly subjects (>80 years): a representative French Nursing Homes survey (2005) (0)
[Genetics of hypertrophic cardiomyopathies: what are the clinical perspectives?]. (1996) (0)
[Towards better education for heart failure patients]. (2005) (0)
Enfin une alternative aux AVK (2010) (0)
554 Factors limiting betablockers prescription by cardiologists in systolic heart failure in France (2006) (0)
Rosiglitazone combination therapy improves ambulatory blood pressure: A 6-month substudy of the RECORD trial in people with type 2 diabetes (2004) (0)
RO 13–6438 IN CONGESTIVE HEART FAILURE: DOSE‐RESPONSE RELATIONSHIP AFTER 3 SINGLE DOSES (1987) (0)
666 Genotypes associated with familial hypertrophic cardiomyopathy in a Portuguese population (2005) (0)
Dealing with a special group: hypertrophic cardiomyopathy. Etiology and prevalence: what is known today. (1999) (0)
P1587 Reasons for non-prescription of angiotensin-converting enzyme inhibitors and beta-blockers in ambulatory heart failure: the SONIC survey (2003) (0)
Contents Vol. 131, 2015 (2015) (0)
HFrEF pharmacological treatment: ivabradine (2018) (0)
329 Predictors of outcome in heart failure with preserved ejection fraction: one year findings rom the Irbesartan in Heart Failure With Preserved Systolic Function Trial (I-PRESERVE) (2008) (0)
[The future of the cardiologist: job and professional conditions]. (2003) (0)
[Hemodynamic study of the systolic anterior motion of the mitral valve in obstructive cardiomyopathy]. (1980) (0)
[Quantitative changes of IgA in rheumatic fever. Comparison with antistreptolysins O, sedimentation speed, activated C protein and leukocyte levels]. (1981) (0)
[Hypertrophic subvalvular aortic stenosis. Morphological and histological data. Medical treatment (author's transl)]. (1980) (0)
Surgical treatment of atrial fibrillation by ultrasounds with epicor system (2013) (0)
Current Approach to Heart Failure (2017) (0)
518 Implementation of ESC guidelines in clinical practice: results of the French IMPACT‐RECO II survey (2007) (0)
Abstract 13770: Geographic Variation in Clinical Course Among Patients Hospitalized for Acute Heart Failure: Insights From ASCEND-HF (2011) (0)
Challenges and Progress in Heart Failure (2012) (0)
[Atrial natriuretic factor in heart insufficiency]. (1992) (0)
[Treatment of chronic cardiac failure in 1997: obvious facts and uncertainties]. (1997) (0)
failurein normal subjects and in patients with heart Muscular blood flow response to submaximal leg (2015) (0)
Impact of home return assistance program (PRADO-IC) on re hospitalisation rate and mortality of hospitalized heart failure patients at one year (2023) (0)
[Cardiac involvement in Friedreich's disease: importance of non-invasive cardiologic investigations. Apropos of 13 cases]. (1983) (0)
[Functional classification of primary myocardial diseases: importance of various further investigations (author's transl)]. (1980) (0)
Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: The ESC-EORP CICD-LT registry. (2022) (0)
Case Report: Myocarditis during Acute Schistosomiasis in Two Travelers (2010) (0)
Abstract 2013: New Onset Atrial Fibrillation is an Independent Predictor of In-Hospital and Short Term Mortality in Patients Admitted with Heart Failure. Results of the Euro Heart Failure Survey (2006) (0)
[Genetics of hypertrophic cardiomyopathies; towards molecular cardiology?]. (1994) (0)
Time to benefit of heart rate reduction with ivabradine in patients with heart failure and reduced ejection fraction. (2023) (0)
[Converting enzyme inhibitors and aims of the objectives of the treatment of cardiac failure]. (1992) (0)
[Management of heart failure in the elderly patient]. (2006) (0)
[Atrial natriuretic factor and cardiac insufficiency]. (1992) (0)
Familial hypertrophic cardiomyopathy: Analysis of several medium-size families with highly informative markers (1992) (0)
Plasma norepinephrine and cardiovascujar hemodynamics during exercise in heart failure (1990) (0)
[Beta-blockers and cardiac insufficiency: a cultural revolution?]. (1998) (0)
184: A simple method to implant epicardial AICD using two separated coils (2013) (0)
The impact of the sinus rhythm restoration during hospitalization on the long-term mortality in patients with acute myocardial infarction accompanied with atrial fibrillation (2007) (0)
Discriminating value of artificial intelligence based models for heart failure readmissions and mortality: A comparison of patients included or not in the PRADO program (2020) (0)
141 Variable clinical expression of familial hypertrophic cardiomyopathy associated with cardiac troponin gene mutations (2005) (0)
Long-term treatment of congestive heart failure with captopril(SQ14, 225) (1982) (0)
499 Rate and reasons of statins prescription in patients with congestive heart failure (2008) (0)
Cohort profile The ESC-EORP Chronic Ischemic Cardiovascular Disease Long-Term (CICD LT) registry. (2019) (0)
Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States. (2016) (0)
SCREENING FOR FAMILIAL HYPERTROPHIC CARDIOMYOPATHY USING BRAIN NATRIURETICPEPTIDE. AUTHORS' REPLY (1999) (0)
Experience fromclinical genetics inhypertrophic cardiomyopathy: proposal fornewdiagnostic criteria inadult membersofaffected families (1997) (0)
[Atrial natriuretic factor, catecholamines and the renin-angiotensin system in cardiac insufficiency. Relation to hemodynamic parameters]. (1988) (0)
Neurohormonal mechanisms in congestive heart failure with special reference to diastolic heart failure. (1999) (0)
698 Lifestyle advice in hospitalized heart failure patients: experience from the EuroHeart Failure survey (2006) (0)
114 Gender‐related differences in the management of patients with congestive heart failure: A French observational study in 1917 patients (2006) (0)
Results ESC Board Elections 2010 - 2012 (2012) (0)
ACE inhibitors in heart failure: the question of dose. (1999) (0)
[Opening of the XIIIth European meeting of the French Society of Cardiology]. (2003) (0)
530 Chronic Renal Insufficiency is associated with an underuse of recommended heart failure therapies (2006) (0)
Genetic heterogeneity of Familial Hypertrophic Cardiomyopathy: Search for a second chromosomal localization (1992) (0)
[50 years of cardiology research]. (1987) (0)
Acute Heart Failure Syndromes: Current and Investigational Pharmacotherapeutic Options (2006) (0)
[Role of arterial hypertension in the cardiac involvement of acromegaly]. (1990) (0)
Predicting Adverse Effects during Angiotensin Receptor Blocker Treatment in Heart Failure: Results from the HEAAL Trial (2010) (0)
[Long-term treatment of severe cardiac failure with captopril (author's transl)]. (1981) (0)
Abstract 3192: Obesity and Its Relationship to Adverse Cardiovascular Outcomes in Older Patients With Heart Failure and Preserved Ejection Fraction in the I-PRESERVE Trial (2009) (0)
Multimodel diagnostic tests to assess heart failure using ECG, chest X ray and echocardiogram in patients with suspected heart failure (2007) (0)
113 Significance of increased plasma BNP level in Patients with Hypertrophic Cardiomyopathy (2010) (0)
734 Comparative value of echocardiography and plasma BNP for monitoring of patients with acute heart failure (2003) (0)
[Exploration of left ventricular function in insulin-dependent diabetics (relation with retinopathy)]. (1986) (0)
285 The changing phenotypic expression of hypertrophic cardiomyopathy throughout life. Insights from a genotyped population with a long follow-up (2006) (0)
326 Anaemia is associated with poor outcome in patients with heart failure and preserved ejection fraction (HF-PEF). Findings from the I-PRESERVE trial (2008) (0)
[Hypertrophic cardiomyopathy: practical application of genetic research]. (1995) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michael Komajda?

Michael Komajda is affiliated with the following schools:

Michael Komajda's Academic­Influence.com Rankings

Michael Komajda's Degrees

Why Is Michael Komajda Influential?

Michael Komajda's Published Works

Published Works

What Schools Are Affiliated With Michael Komajda?

Michael Komajda's AcademicInfluence.com Rankings